Using Multilevel Modeling to Examine Blunted Neural Responses to Reward in Major Depression

Christopher J. Brush, Peter J. Ehmann, Greg Hajcak, Edward A. Selby, and Brandon L. Alderman

ABSTRACT

BACKGROUND: Major depressive disorder (MDD) is a pernicious disorder characterized by deficits in reward processing. A better understanding of these deficits may help to elucidate the underlying pathophysiology and guide treatment development.

METHODS: This study assessed reward positivity and feedback negativity event-related potentials and their difference scores elicited in response to monetary gains and losses among 100 young adults (52 with MDD). Multilevel modeling was used to assess individual- and trial-level change in neural responses over time.

RESULTS: Trial-level analyses indicated that a diagnosis of MDD and depressive symptom severity significantly moderated the trajectory of reward positivity, with individuals with higher symptoms of depression demonstrating less sensitivity to rewards over time.

CONCLUSIONS: These results provide further support for reward dysfunction in MDD and highlight important individual differences in the trajectory of neural responses to reward. Future studies are warranted to investigate reward sensitivity over time to elucidate important individual- and trial-level differences in reward processing.

Keywords: Depression, ERPs, Feedback negativity, Multilevel modeling, Reward positivity, Reward sensitivity

https://doi.org/10.1016/j.bpsc.2018.04.003
Reward Processing in Depression

caudate, amygdala, medial prefrontal cortex, and orbitofrontal cortex were involved in generating RewP; meanwhile, Foti et al. (29) used source localization techniques and observed increased reward-related activity in the basal ganglia. Furthermore, a simultaneous ERP and fMRI study observed that trial-to-trial ERP variation to rewards predicted hemodynamic activity across the reward circuit (26). All of these brain structures are implicated in the mesocorticolimbic dopamine system, an important system in reward circuitry (31), suggesting that reward-related ERPs may be used to detect reward processing deficits in depression.

Typically, ERP studies average data across many trials of the same type to isolate a psychological process of interest and are traditionally analyzed using repeated measures analysis of variance designs. Recently, Volpert-Esmond et al. (32) noted that the underlying assumption of the averaging process is that neural activity does not vary across the course of an experiment. They provided two examples demonstrating how multilevel modeling (MLM) can be used to examine change in neurophysiological processes over the course of an experimental session, while accounting for unique sources of variance (e.g., individual- and trial-level variability).

MLM is particularly relevant for studying the neural response to rewards and losses in gambling paradigms as well as the temporal dynamics of reward processing in depression. For instance, Heller et al. (33) collected fMRI data during an emotion regulation paradigm to test whether depression reflects deficits in the ability to sustain activity in neural structures involved in reward, motivation, and positive affect over a 37-minute scan session. Individuals with MDD were unable to sustain nucleus accumbens activity over time compared with control individuals, which was related to individual differences in self-reported positive affect. In a separate study, antidepressant treatment–induced change in the sustained engagement of prefrontal-striatal circuitry predicted improvements in the experience of positive emotion in daily life (34). In both studies, fMRI data were averaged from the first and second halves of the experimental session to examine engagement over time. Incorporating MLM within ERP experiments allows for the detection of subtle changes in psychological processes that occur across a particular task or experiment. Nonetheless, these findings are provocative and suggest important temporal dynamics in reward processing that can be examined in a laboratory setting.

To date, no study has extended the previous findings of blunted reward processing in depression (14,23,24) using MLM to examine changes in reward processing over the course of an experiment. Understanding neural responses to reward across time may provide insight into mechanisms underlying MDD. Therefore, we examined individual- and trial-level differences in RewP, FN, and ΔRewP using MLM to track the trajectory of responses over successive reward and loss trials. We hypothesized an attenuated ΔRewP for individuals with MDD relative to healthy control individuals. Based on the findings of impaired striatal engagement in depression (33), individuals with MDD were expected to exhibit reduced RewP over time relative to control participants, as indicated by negative linear change across the task. Depression symptom severity was also examined as a moderator of RewP and FN and was expected to be associated with reduced RewP over time. Lastly, we examined the psychometrics of these feedback-related ERPs using internal consistency measures to further establish their utility in psychopathology research (12).

METHODS AND MATERIALS

Participants

Individuals of all ethnic origins between 18 and 25 years of age (N = 101) were recruited from university counseling and psychiatric clinics and advertisements posted around the surrounding community. All participants were interviewed using the Mini-International Neuropsychiatric Interview and had normal or corrected-to-normal vision. Exclusion criteria included any history or presence of bipolar spectrum disorder, schizophrenia, self-injurious or suicidal ideation, or neurological disorders or injuries resulting in a loss of consciousness. One participant was removed from the analyses owing to poor EEG data quality, resulting in 100 participants (71 female participants; 52 participants with MDD) being included in the analyses. The final sample composition was sufficiently powered to test the primary hypothesis (see the Supplement for the a priori power analysis) and included 38 Asian individuals, 29 white individuals, 13 Hispanic individuals, 12 African-American individuals, and 8 individuals self-identifying as more than one race. Participants provided written informed consent, and the study was approved by the university’s institutional review board.

MDD Diagnosis

The Mini-International Neuropsychiatric Interview is a brief, structured interview that is highly reliable (35) and widely used for evaluating diagnoses of psychiatric disorders according to DSM-IV, DSM-5, and ICD-10. The Mini-International Neuropsychiatric Interview was used to screen for Axis I disorders and presence of a current major depressive episode. All interviewers had previous experience in administering structured clinical interviews.

Depression Symptom Severity

The Beck Depression Inventory-II (BDI-II) (36), a 21-item self-report inventory, was used to assess depression symptom severity over the past 2 weeks. Each item is scored on a 4-point scale (0–3), with a range of 0 to 63. The BDI-II scores in this sample demonstrated high internal consistency (Cronbach’s α = .92).

Doors Task

The doors task (14) was administered using E-Prime Professional 2.0 software (Psychology Software Tools, Inc., Sharpsburg, PA) and consisted of five blocks of 20 trials. On each trial, a fixation cross was presented at the center of the screen for 1000 ms followed by the presentation of two doors, which remained on the screen until participants made a left or right button press corresponding to the left or right door using a Logitech F310 response gamepad (Logitech, Newark, CA). Following stimulus offset, another fixation cross was presented for 2000 ms before displaying the feedback stimulus for 2000 ms. Feedback indicated whether the participant won $0.50 (reward trial) or lost $0.25 (loss trial), which was represented by a green upward arrow or a red downward arrow, respectively. After feedback, another fixation cross was
presented for 1500 ms, which was followed by a short break before the next trial. Fifty reward and 50 loss trials were presented on a monitor at a distance of 70 cm centered to the nasion, with vertical and horizontal visual angles of 1.2° and 6.6°, respectively. Participants were compensated their winnings ($12.50) following the task.

**ERP Processing and Measurement**

Continuous EEG was recorded from a 33-electrode actiCAP system (Brain Products, GmbH, Gilching, Germany) arranged according to the 10/20 guidelines. The electro-oculogram activity was recorded from two electrodes placed 2 cm outside the outer canthus of the left eye and 2 cm below the right eye. EEG was amplified using an Electrical Geodesics, Inc. (Eugene, OR) system (20,000 nominal gain, bandpass of 0.10–100 Hz) and sampled at 500 Hz with a 24-bit analog-to-digital converter referenced to the vertex electrode (Cz) at acquisition. Impedances were kept below 20 kΩ throughout recording.

EEG data were exported to EEGLAB toolbox version 14.1.1 (32) in MATLAB version R2016b (The MathWorks, Inc., Natick, MA) for data preprocessing. Data were bandpass filtered using a second-order infinite impulse response Butterworth filter of 0.10 to 30 Hz and adjusted for direct current offset. EEG data were visually inspected for artifacts or extreme offsets and segmented to create feedback-locked epochs for gain and loss trials separately using a −200- to 800-ms time window. Oculomotor artifacts were removed using ICA blink templates provided by ERP PCA toolkit version 2.6.3 (33) and generated from the current dataset (see the Supplement for additional artifact rejection criteria). Epochs were re-referenced to the mean of the two mastoids (TP9, TP10), averaged separately by rewards and losses, and baseline corrected using the 200-ms prestimulus interval.

Consistent with previous research (14,19,37–39) and the maximal activity at frontocentral sites in the present study, RewP (rewards) and FN (losses) were assessed at FCz. Feedback-locked amplitudes were measured as the mean voltage in a time window 200 to 300 ms post feedback onset and were determined by visual inspection of the grand average waveform collapsed across participants and feedback types to minimize bias (40). The gain-loss difference waveform (ΔRewP), defined as RewP (rewards) minus FN (losses), was derived to isolate reward-related activity (14,38). The regression-based residualized difference (ΔRewP_resid) score was also calculated, as recent research suggests that it may be slightly more reliable than subtraction-based differences scores (19,41). Internal consistency measures were quantified using classical test theory and generalizability theory estimates of dependability (42) (see the Supplement for detailed information about the reliability and dependability estimates).

**Statistical Analyses**

All analyses were performed using IBM SPSS version 24 (IBM Corp., Armonk, NY). To minimize the influence of poor data quality, participants with fewer EEG trials than needed to obtain a dependability point estimate of 0.80 were removed. Removal of 1 participant was due to this criterion. All MDD and control participants had a minimum of 33 trials (range, 33–100) and 32 (range, 32–100) trials, respectively.

A 2 (feedback type: gain, loss) × 2 (group: MDD, control) repeated measures analysis of variance was used to examine group-level effects in RewP and FN, while an independent-samples t test was conducted to test the primary hypothesis of differences in ΔRewP (ΔRewP_resid) by depression status. A two-tailed α level of .05 was used, and follow-up tests were adjusted using the Bonferroni correction (p_corrected = .05/2 = .025).

RewP and FN were analyzed using MLM. Owing to the nested structure of the data, two level models were used to examine slopes of RewP and FN across the doors task. MLM accounts for individual differences in baseline responses at the beginning of the experiment (trial 1; random intercept) and changes over time (slopes) in a way that cannot be modeled with traditional approaches. MLM also partitions unique sources of variance, where the predictor variables, such as current diagnosis and depressive severity, are used to predict individual-specific change. MLM was used to model variation in RewP and FN across doors task trials as well as the covariance of nonindependence between repeated measures. These types of models are ideal for ERP data, as MLMs are robust to occasional missing trial-level data (32,43).

For the current models, the dependent variable was within-subject RewP and FN amplitudes. For level 1 (during each trial), predictors were trial (continuous; represents task trial number and linear growth) and task feedback type (dichotomous; 0 = losses, 1 = gains). For level 2 (for each participant), separate models included diagnostic status (dichotomous; 0 = control, 1 = MDD) and depressive symptom severity (continuous; grand-mean centered BDI-II score) as predictors. Model 1 was constructed to determine the prediction of current depression status on RewP and FN. Cross-level interactions between depression status and trial were included to examine the moderating influence of depression status on RewP and FN changes from the beginning to the end of the experiment. Additionally, another cross-level interaction between depression status, feedback type, and trial was included in the model to examine whether depression status served as a moderator of feedback type on RewP and FN over time. Model 2 included the same parameters; however, depression symptom severity was substituted for diagnostic status to examine symptom severity rather than simple presence of a diagnosis. For both models, trial was shifted so that the first trial corresponded with the intercept (t = 0). Thus, the 50 reward and 50 loss trials ranged from 0 to 49 in the MLM analyses. Dichotomous variables, such as depression status, cannot be included as a random effect in mixed models. Whereas trial was retained as a random effect in both models, based on parsimony and the nonsignificant finding for depression severity as a random effect, we retained both diagnostic status and depression severity as fixed effects in the models. Finally, the models used restricted maximum likelihood estimation and an unstructured covariance matrix. See the Supplement for model specifications.

**RESULTS**

Demographic and clinical characteristics are shown in Table 1. Bivariate correlations between depressive symptoms and feedback-related ERP amplitudes are reported in Table 2, and Table 3 displays the internal consistency measures.
**Table 1. Demographic and Clinical Characteristics**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>MDD (n = 52)</th>
<th>Control (n = 48)</th>
<th>Test Statistic</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender, Male, n (%)</td>
<td>12 (23.6%)</td>
<td>17 (35.4%)</td>
<td>χ² = 1.8</td>
<td>.17</td>
</tr>
<tr>
<td>Age, Years</td>
<td>20.0 (1.4)</td>
<td>20.0 (1.5)</td>
<td>t = 0.27</td>
<td>.79</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.6 (3.6)</td>
<td>22.9 (3.6)</td>
<td>t = 0.96</td>
<td>.34</td>
</tr>
<tr>
<td>BDI-II Total Score</td>
<td>24.0 (8.8)</td>
<td>7.9 (5.9)</td>
<td>t = 10.83</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>BAI Total Score</td>
<td>11.0 (9.1)</td>
<td>8.4 (6.3)</td>
<td>t = 1.65</td>
<td>.10</td>
</tr>
<tr>
<td>Comorbidities, n (%)</td>
<td>13 (25%)</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medicated, n (%)</td>
<td>5 (10%)</td>
<td>N/A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values are mean (SD), unless otherwise indicated.

BAI, Beck Anxiety Inventory; BDI-II, Beck Depression Inventory-II; BMI, body mass index; MDD, major depressive disorder; N/A, not applicable.

*Generalized anxiety disorder (n = 10), posttraumatic stress disorder (n = 2), social anxiety disorder (n = 2), panic disorder (n = 1), substance-related disorder (n = 1); 3 participants had two of these comorbidities.

**Table 2. Correlations Between Depression Symptom Severity and Feedback-Related ERPs**

<table>
<thead>
<tr>
<th>ERP Measure</th>
<th>BDI-II Total Score (N = 100)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RewP</td>
<td>−0.19</td>
</tr>
<tr>
<td>FN</td>
<td>−0.07</td>
</tr>
<tr>
<td>ΔRewP</td>
<td>−0.25*</td>
</tr>
<tr>
<td>ΔRewP_red</td>
<td>−0.23*</td>
</tr>
</tbody>
</table>

BDI-II, Beck Depression Inventory-II; ERP, event-related potential; FN, feedback negativity; RewP, reward positivity; ΔRewP, difference between RewP and FN; ΔRewP_red, regression-based residualized difference between RewP and FN.

*p < .05.

**Table 3. Psychometric Properties of Feedback-Related ERPs**

<table>
<thead>
<tr>
<th>Measure</th>
<th>RewP</th>
<th>FN</th>
<th>ΔRewP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minimum Number of Trials*</td>
<td>9</td>
<td>9</td>
<td>—</td>
</tr>
<tr>
<td>Control</td>
<td>7</td>
<td>8</td>
<td>—</td>
</tr>
<tr>
<td>Split-half Reliability</td>
<td>0.95</td>
<td>0.95</td>
<td>0.58</td>
</tr>
<tr>
<td>MDD</td>
<td>0.97</td>
<td>0.96</td>
<td>0.53</td>
</tr>
<tr>
<td>Dependability (95% CI)</td>
<td>0.95 (0.93, 0.97)</td>
<td>0.96 (0.93, 0.97)</td>
<td>—</td>
</tr>
<tr>
<td>Control</td>
<td>0.97 (0.95, 0.98)</td>
<td>0.96 (0.95, 0.98)</td>
<td>—</td>
</tr>
</tbody>
</table>

CI, confidence interval; ERP, event-related potential; FN, feedback negativity; MDD, major depressive disorder; RewP, reward positivity; ΔRewP, difference between RewP and FN.

*Denotes minimum number of trials to reach the minimum dependability point estimate of ≥.80.

**ERPs Analyses**

Grand averaged parent and difference waveforms depicting RewP, FN, and ΔRewP by group are presented in Figure 1. A significant electrode site main effect revealed that ERP amplitudes were largest at FCz relative to Fz and Cz sites (F[2,198] = 111.59, p < .001, η² = .53). The expected main effect of feedback type (F[1,98] = 109.00, p < .001, η² = .53) indicated more positive amplitude for reward (RewP = 11.87 ± 5.65 μV) relative to loss trials (FN = 8.65 ± 6.05 μV). A significant feedback type × group interaction was observed (F[1,98] = 13.00, p < .001, η² = .12). Decomposition of the interaction revealed a trend toward a smaller RewP for individuals with MDD (RewP = 10.57 ± 6.43 μV) relative to control participants (RewP = 13.28 ± 6.48 μV) (t[98] = 2.10, p_corrected = .04, d = 0.42). Conversely, FN amplitude did not differ between groups (t[98] = 0.49, p_corrected = .62, d = 0.10). Individuals with MDD had a significantly smaller ΔRewP (2.01 ± 2.52 μV) than control participants (4.13 ± 3.33 μV) (t[98] = 3.61, p < .001, d = 0.72), which was also observed in the regression-based ΔRewP (MDD = −1.80 ± 4.68 μV; control = 1.95 ± 6.24 μV) (t[98] = 3.42, p < .01, d = 0.68). See the Supplement for analyses related to the P2 component.

**MLM Analyses**

For the unconditional model, the mean intercept (b = 10.29, SE = 0.6, t[98] = 16.9, p < .001) and variance of the intercept across individuals (b = 36.29, SE = 5.28, Wald = 6.87, p < .001) were significant. The intraclass correlation coefficient was 0.316, suggesting approximately 31.6% of the variance in feedback-related amplitude was accounted for by between-individual variability, while 68.4% was accounted for within individuals.

Model 1 assessed the moderating influence of diagnostic status on initial reward response and changes in RewP/FN amplitude over time. There was a significant main effect of feedback type (b = 2.59, SE = 0.35, t[98] = 7.32, p < .001), indicating that RewP was 2.59 μV greater than FN amplitude. Although there was no significant main effect of trial, there was significant individual-level variability in RewP/FN amplitude across trials (b = 0.004, SE = 0.001, Wald = 3.65, p < .001). Additionally, there was a significant cross-level feedback type × trial interaction (b = 0.05, SE = 0.01, t[98] = 3.23, p < .001), indicating positive linear growth for RewP across time (b = 0.03, p < .01, 95% confidence interval [CI] [0.01, 0.05]). Current depression status failed to moderate initial (trial 1) RewP/FN amplitude (b = −1.20, SE = 1.26, t[98] = −0.96, p = .34). Lastly, there was a significant cross-level interaction between diagnostic status × feedback type × trial (b = −0.06, SE = 0.01, t[98] = −4.72, p < .001). Follow-up simple slopes analysis revealed a significant increase in RewP amplitude only for control participants (b = 0.04, p < .05, 95% CI [0.01, 0.07]), whereas all other slopes were nonsignificant (Figure 2).

Model 2 examined the influence of depression severity on initial reward response and slope of change over time. Similar to model 1, model 2 findings indicated a significant feedback type main effect (b = 2.59, SE = 0.36, t[98] = 7.30, p < .001) but no significant feedback type × trial interaction (b = 0.02, SE = 0.01, t[98] = 1.22, p = .23). Although the main effect of trial was nonsignificant, there was significant individual-level variability in RewP/FN amplitude across trials (b = 0.004, SE = 0.001, Wald = 3.64, p < .001). Despite the intercept also varying significantly across individuals, depression severity failed to moderate initial (trial 1) RewP/FN amplitude (b = −0.06, SE = 0.06, t[98] = −1.03, p = .30). Notably, a significant cross-level interaction of depression severity × feedback type × trial emerged (b = −0.002, SE = 0.001, t[98] = −3.38, p < .01). Follow-up simple slopes analyses for RewP indicated a...
positive and significant slope coefficient at low levels of depression severity (1 SD below the BDI-II mean) ($b = 0.04$, $p < 0.05$, 95% CI [0.01, 0.07]) and average levels of depression (at the BDI-II mean) ($b = 0.03$, $p < 0.01$, 95% CI [0.01, 0.05]) such that there was a potentiated RewP over time for individuals with lower symptoms of depression (Figure 3). In contrast, all other slopes were nonsignificant. Findings for each model are summarized in Table 4. Findings from models 1 and 2 indicate no differences in initial reward sensitivity (intercept), while results from models 1 and 2 suggest that depression moderates RewP across trials (slope), with a potentiated response over time among individuals with lower symptoms of depression.

**DISCUSSION**

The goal of this study was to examine the neural response to reward and loss feedback in individuals with clinical depression relative to control participants and to extend this line of research by examining individual and trial-level differences in RewP, FN, and $\Delta$RewP over the course of the experiment using MLM. Similar to previous studies (21, 24), a blunted $\Delta$RewP was observed among individuals with MDD—an effect that was primarily driven by the neural response to rewards. Additionally, feedback-related ERPs demonstrated acceptable-to-excellent psychometric properties, further supporting their utility in examining individual differences in psychopathology (44). Although current MDD diagnosis and depression severity failed to moderate initial reward processing (i.e., intercept), both MDD diagnosis and depressive symptom severity influenced the trajectory of neural responses over the course of the experiment (i.e., slope). Specifically, trial-level analyses indicated that a diagnosis of MDD and depressive symptom severity significantly moderated reward responses over time, with individuals with higher symptoms of depression demonstrating less sensitivity to rewards over time. These findings could not have been identified outside of an MLM framework, highlighting the potential of incorporating MLM in future ERP studies.

The current findings add to previous research indicating aberrant reward-related brain activity among individuals with MDD (21, 24). In particular, individuals with current MDD demonstrated a blunted $\Delta$RewP that was primarily driven by an attenuated response to rewards relative to the neural response observed among healthy control participants. Specifically, healthy control participants showed positive linear growth in RewP across time, a finding not found among individuals with MDD. The inclusion of symptom severity as a moderator revealed that individuals with lower symptoms of depression showed a potentiated response to gains as evidenced by a positive linear slope across the doors task. Such a trend was
not observed among individuals reporting greater depression severity. These findings suggest that greater decreases in neural response to rewards in depressed individuals relative to control participants suggests that a normal RewP response may be characterized by a slight increase over time, which is not characteristic of depressed individuals. This is the first study to examine trial-level differences in reward sensitivity across monetary reward or feedback paradigms, particularly among depressed individuals, and future studies are warranted to replicate these findings.

Individuals with MDD often display poorer modulation of behavior based on prior reward contingencies (45), and the current findings of blunted RewP across time, relative to control participants, may in part reflect this reward system dysfunction. Abnormalities in reward are central to many models of depression—and a blunted neural response to rewards has emerged as a prospective predictor of onset of depression (46). In a sample of 444 adolescents with no history of depression, Nelson et al. (46) found that an attenuated ΔRewP at baseline was a significant predictor of first-onset depressive disorder and greater dysphoria 18 months later. Future prediction studies should include MLM-based analyses in the assessment of risk for depression. In addition, as a blunted ΔRewP represents a composite of reward- and loss-related activity, future research should incorporate time-frequency representations of reward (e.g., reward-related delta) and loss (e.g., loss-related theta) to provide further insight into the underlying nature of reward-related network disruptions in depression (29,47).

The patterns of responding observed are consistent with the notion that depression is characterized by aberrant reward processing, possibly owing to blunted phasic dopaminergic signaling (25). Impaired mesocorticolimbic dopamine pathways (including ventral and dorsal striatal regions) have been hypothesized in MDD and may be related to the decreased motivation and ability to experience reward. To the extent that the RewP indexes individual differences in reward sensitivity, the current data of suppressed reward response over time in individuals with high symptoms of depression is consistent with this hypothesis. In particular, it may shed light into conceptualizations of depression that highlight its core features of low positive affect and anhedonia (48,49). Depressed individuals have displayed an inability to sustain nucleus accumbens and caudate activity during reward processing (8,33), which may be related to the impaired RewP across time.

Collectively, the current findings suggest that individuals with MDD are characterized by an attenuated response to reward. Additionally, individuals with lower depressive symptoms were increasingly responsive to rewards across the task, while individuals reporting greater symptom severity demonstrated relatively sustained RewP over time. These findings contribute to evidence suggesting that depression is associated with impairments in reward processing and advance the investigation of individual differences and within-trial response patterns in reward sensitivity. As such, reward system dysfunction may be a promising target for depression, and examining changes in RewP over time may help to identify vulnerable individuals.

**ACKNOWLEDGMENTS AND DISCLOSURES**

We thank Rutgers University Counseling and Psychological Services for assistance with participant referrals and recruitment and Anthony Bocchine for his assistance with data collection and manuscript preparation.

---

**Figure 3.** Trajectory of difference between reward positivity and feedback negativity (ΔRewP) amplitude across the course of the doors task for individuals reporting low, average, and high symptoms of depression. Note that groups with low, average, and high depressive symptoms were created by splitting the sample based on −1 SD (low), 0 SD (mean), and +1 SD (high) from the sample Beck Depression Inventory (BDI)-II mean.

---

**Table 4. Multilevel Models of RewP and FN Across Time**

<table>
<thead>
<tr>
<th>Variable</th>
<th>b</th>
<th>SE</th>
<th>t</th>
<th>df</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1&lt;sup&gt;a&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intercept</td>
<td>0.16</td>
<td>0.92</td>
<td>10.0</td>
<td>112.4</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Trial</td>
<td>&lt; -0.001</td>
<td>0.02</td>
<td>&lt; -0.1</td>
<td>171.2</td>
<td>.98</td>
</tr>
<tr>
<td>Feedback type&lt;sup&gt;b&lt;/sup&gt;</td>
<td>2.59</td>
<td>0.35</td>
<td>7.3</td>
<td>9038.5</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Feedback type × trial&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.05</td>
<td>0.01</td>
<td>3.2</td>
<td>9056.3</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Diagnostic status</td>
<td>-1.20</td>
<td>1.26</td>
<td>-1.0</td>
<td>103.9</td>
<td>.34</td>
</tr>
<tr>
<td>Diagnostic status × trial&lt;sup&gt;c&lt;/sup&gt;</td>
<td>0.02</td>
<td>0.02</td>
<td>1.1</td>
<td>126.4</td>
<td>.27</td>
</tr>
<tr>
<td>Diagnostic status × feedback type × trial&lt;sup&gt;c&lt;/sup&gt;</td>
<td>-0.06</td>
<td>0.01</td>
<td>-4.7</td>
<td>9053.6</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Model 2&lt;sup&gt;d&lt;/sup&gt;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intercept</td>
<td>8.54</td>
<td>0.65</td>
<td>13.1</td>
<td>121.3</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Trial</td>
<td>0.01</td>
<td>0.01</td>
<td>1.0</td>
<td>218.9</td>
<td>.33</td>
</tr>
<tr>
<td>Feedback type&lt;sup&gt;e&lt;/sup&gt;</td>
<td>2.59</td>
<td>0.36</td>
<td>7.3</td>
<td>9038.6</td>
<td>&lt; .001</td>
</tr>
<tr>
<td>Feedback type × trial</td>
<td>0.02</td>
<td>0.01</td>
<td>1.2</td>
<td>9052.1</td>
<td>.23</td>
</tr>
<tr>
<td>Depression severity</td>
<td>-0.06</td>
<td>0.06</td>
<td>-1.0</td>
<td>103.7</td>
<td>.30</td>
</tr>
<tr>
<td>Depression severity × trial</td>
<td>&lt; 0.001</td>
<td>&lt; 0.001</td>
<td>0.7</td>
<td>124.4</td>
<td>.50</td>
</tr>
<tr>
<td>Depression severity × feedback type × trial&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-0.002</td>
<td>0.001</td>
<td>-3.4</td>
<td>9042.6</td>
<td>&lt; .001</td>
</tr>
</tbody>
</table>

AIC, Akaike information criterion; FN, feedback negativity; RewP, reward positivity.

<sup>a</sup>D for model 1, the reduced model with the inclusion of main effects yields an AIC of 66657.4. The inclusion of interactions and Trial as a fixed effect results in an AIC of 66649.1. The inclusion of Trial as a random effect, which is represented in the full model, improved model fit, as indicated by an AIC of 66616.2.

<sup>b</sup>For model 2, the reduced model with the inclusion of main effects yields an AIC of 66663.4. The inclusion of interactions and Trial as a fixed effect results in an AIC of 66649.1. The inclusion of Trial as a random effect, which is represented in the full model, improved model fit, as indicated by an AIC of 66642.2.

Downloaded for Anonymous User (n/a) at Florida State University from ClinicalKey.com by Elsevier on June 04, 2019. For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
The authors report no biomedical financial interests or potential conflicts of interest.

**ARTICLE INFORMATION**
From the Department of Kinesiology and Health (CJB, PJE, BLA), Rutgers, The State University of New Jersey, New Brunswick; Department of Psychology (EAS), Rutgers, The State University of New Jersey, Piscataway, New Jersey; and Department of Psychology (GH), Florida State University, Tallahassee, Florida.

Address correspondence to Brandon L. Alderman, Ph.D., Department of Kinesiology and Health, Rutgers, The State University of New Jersey, 70 Lipman Drive, New Brunswick, NJ 08901; E-mail: alderman@rutgers.edu.

Received Jan 16, 2018; revised Mar 19, 2018; accepted Apr 3, 2018.

Supplementary material cited in this article is available online at https://doi.org/10.1016/j.bpsc.2018.04.003.

**REFERENCES**


Reward Processing in Depression


